Evidence map›Paper›PMID 32301368›Full record

ArticleJournal of the American Heart Association2020

Interleukin-22 Directly Activates Myocardial STAT3 (Signal Transducer and Activator of Transcription-3) Signaling Pathway and Prevents Myocardial Ischemia Reperfusion Injury.

Jinya Takahashi, Mai Yamamoto, Hideo Yasukawa, Shoichiro Nohara, Takanobu Nagata, Koutatsu Shimozono, Toshiyuki Yanai, Tomoko Sasaki, Kota Okabe, Tatsuhiro Shibata and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. IL-22 Attenuates Pressure Overload-Induced Heart Failure and Inflammation.Journal of cardiovascular translational research · 2025
    Article
  8. Review
  9. The Role of P53 in Myocardial Ischemia-Reperfusion Injury.Cardiovascular drugs and therapy · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Mitochondrial Respiration inCurrent issues in molecular biology · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Jinya TakahashiDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Mai YamamotoCardiovascular Research Institute Kurume University Kurume Japan.
Hideo YasukawaDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Shoichiro NoharaDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Takanobu NagataDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Koutatsu ShimozonoDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Toshiyuki YanaiDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Tomoko SasakiDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Kota OkabeDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Tatsuhiro ShibataDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Kazutoshi MawatariDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Tatsuyuki KakumaBiostatistics Center Kurume University Kurume Japan.
Hiroki AokiCardiovascular Research Institute Kurume University Kurume Japan.
Yoshihiro FukumotoDivision of Cardiovascular Medicine Department of Internal Medicine Kurume University School of Medicine Kurume Japan.
Kurume University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Interleukin (IL)-22, a member of the IL-10 cytokine family, is the only known cytokine that is secreted by immune cells but does not target immune cells; it mainly targets epithelial cells. In this study, we aimed to determine whether IL-22 administration could activate the myocardial STAT3 (signal transducer and activator of transcription-3) signaling pathway, and thus prevent myocardial injury, in a mouse model of ischemia reperfusion injury. METHODS AND RESULTS We evaluated the STAT3 activation after IL-22 injection by Western blot analysis and immunostaining for phosphorylated STAT3 in the heart and found that STAT3 activation in heart tissue rapidly peaked after IL-22 injection. Coimmunostaining of phosphorylated STAT3 and α-actinin revealed that STAT3 activation occurred in cardiomyocytes after IL-22 administration. In heart tissue from intact mice, real-time PCR demonstrated significant expression of IL-22 receptor subunit 1, and coimmunostaining of IL-22 receptor subunit 1 and α-actinin showed IL-22 receptor subunit 1 expression in cardiomyocytes. In cultured cardiomyocytes, IL-22 activated STAT3, and we detected IL-22 receptor subunit 1 expression. Overall, these results indicated that IL-22 directly activated the myocardial IL-22-receptor subunit 1-STAT3 signaling pathway. Following ischemia reperfusion, compared with PBS-treated mice, IL-22-treated mice exhibited a significantly reduced infarct size, significantly reduced myocardial apoptosis, and significantly enhanced phosphorylated STAT3 expression. Moreover, heart tissue from IL-22-treated mice exhibited a significantly reduced expression ratio of phosphorylated p53 to p53. CONCLUSIONS Our present findings suggest that IL-22 directly activated the myocardial STAT3 signaling pathway and acted as a cardioprotective cytokine to ameliorate acute myocardial infarction after ischemia reperfusion.

Indexed as

AnimalsApoptosisCells, CulturedDisease Models, AnimalInterleukin-22InterleukinsMaleMice, Inbred C57BLMyocardial InfarctionMyocardial Reperfusion InjuryMyocytes, CardiacPhosphorylationReceptors, InterleukinSignal TransductionSTAT3 Transcription FactorInterleukin-22interleukin-22 receptorInterleukinsReceptors, InterleukinStat3 protein, mouseSTAT3 Transcription Factorapoptosiscytokineischemia reperfusion injurysignal transduction

Identifiers

PMID32301368
PMCPMC7428538
OpenAlexW3016614325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.